U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].

Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...